Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response-Reference-Cited by-同舟云学术

Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response

Published:2016-01 Issue:2 Volume:17 Page:103-109
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Huang Eric¹²,Maciukiewicz Malgorzata²,Zai Clement C²,Tiwari Arun K²,Li Jiang³,Potkin Steven G⁴,Lieberman Jeffrey A⁵,Meltzer Herbert Y³,Müller Daniel J²⁶,Kennedy James L²⁶

Affiliation:

1. 1 King's College Circle, Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, M5S 1A8, Canada

2. 250 College Street, Pharmacogenetic Research Clinic, Centre for Addiction & Mental Health, Toronto, ON, M5T 1R8, Canada

3. 303 East Chicago Avenue, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA

4. 5251 California Avenue, Department of Psychiatry & Human Behavior, University of California, Irvine, CA 92617, USA

5. 1051 Riverside Drive, Department of Psychiatry, Columbia University Medical Center, New York, NY 10032, USA

6. 250 College Street, Department of Psychiatry, University of Toronto, Toronto, ON, M5T 1R8, Canada

Abstract

Aim: The recent Psychiatric Genomics Consortium genome-wide association study identified an SNP, rs2514218, located 47kb upstream of the DRD2 gene to be associated with risk for schizophrenia (p = 2.75e-11). Since all antipsychotics bind to dopamine D2 receptors, we examined rs2514218 in relation to response to antipsychotic treatment. Patients & methods: We investigated the SNP in relation to treatment response in a prospective study consisting of 208 patients (151 Caucasians, 42 African–Americans and 15 others) treated with clozapine for 6 months. Results: rs2514218 was associated with total score change in the brief psychiatric rating scale under an additive model (pcorr= 0.033). Conclusion: Our finding provides evidence for rs2514218 association with antipsychotic response, but further replication is required before firm conclusions can be drawn.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.15.155

Reference40 articles.

1. Biological insights from 108 schizophrenia-associated genetic loci

2. Dopamine D2 Receptors as Treatment Targets in Schizophrenia

3. Antipsychotic drug doses and neuroleptic/dopamine receptors

4. Antipsychotic Drugs, Neurotransmitters, and Schizophrenia

5. Half a century of antipsychotics and still a central role for dopamine D2 receptors

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal;Biomedicines;2023-03-14

2. Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review;Genes;2023-03-10

3. Pharmacogenomic screening for agranulocytosis and efficacy with clozapine;Journal of Translational Genetics and Genomics;2023

4. Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives;Frontiers in Pharmacology;2022-10-12

5. Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians’ attitudes to sociocultural differences between patients across the globe;Translational Psychiatry;2022-10-11